Bioventus

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bioventus reports Q4 revenue decline, focuses on operational efficiency

Bioventus faced revenue challenges in Q4 2022 but demonstrated strength in key segments like Surgical Solutions and international growth.
Actions taken to enhance earnings and financial stability show a commitment to improving performance and regaining investor confidence.
Challenges around revenue decline, gross margin impact, and uncertainty require strategic focus on debt management and operational efficiency.

Bioventus reports Q1 revenue growth, addresses market challenges and opportunities

Bioventus delivered solid Q1 performance with revenue growth and improved EBITDA.
Challenges in the HA market and potential divestitures were key discussion points.
Opportunities lie in revenue growth strategies, cost management, and portfolio optimization.
Overall, Bioventus aims to leverage strengths for sustained growth and profitability.

Bioventus reports Q2 growth, eyes talent acquisition for future

Bioventus showcased financial achievements in Q2 2023, with a focus on improving execution, profitability, and reducing leverage.
Despite revenue decline, the company's adjusted EBITDA increased, driven by strong volume growth in pain treatments and international segment expansion.
Management's confidence in the product portfolio, growth prospects, and talent acquisition bodes well for Bioventus's future performance and strategic direction.

Bioventus reports Q3 resilience, eyes growth in international markets

Bioventus showcased resilience with strong performance in key segments despite revenue decline.
The company's strategic focus on growth drivers and international expansion bodes well for future prospects.
Challenges in certain segments are being addressed with plans for improvement and return to growth.
2024 plans emphasize investments in sales, R&D, and portfolio optimization for sustained growth.

Bioventus reports robust Q4 earnings, sets ambitious goals for 2024

Bioventus delivered strong financial performance in Q4 2023 and outlined ambitious goals for 2024.
The company's focus on revenue growth, operational efficiency, and cash flow improvement reflects a strategic approach to value creation.
While facing debt leverage challenges, Bioventus aims to leverage its strengths and opportunities to drive sustainable growth.
Investors should monitor Bioventus' progress in executing its 2024 priorities and achieving the set financial targets.

Bioventus excels in Q1 2024, focuses on growth and profitability

Bioventus demonstrated robust performance in Q1 2024, driven by revenue growth and margin improvement.
While facing challenges in international growth and operational areas, the company remains optimistic about long-term prospects.
Management's strategic priorities and financial achievements position Bioventus well for future growth and profitability.
Analyst inquiries highlighted key areas for improvement and strategic focus for Bioventus moving forward.

Bioventus excels in Q2 2024, focuses on core growth

Bioventus reported a strong Q2 2024 with revenue growth, improved profitability, and strategic divestment decision
The company aims to drive double-digit revenue and EBITDA growth for the rest of 2024 and into 2025
Despite challenges in Restorative Therapies sales, Bioventus remains focused on core segments for growth
Enhanced financial guidance and operational efficiency position Bioventus for continued success and expansion

Bioventus posts strong Q3 results, eyes growth in medical solutions

Bioventus (BVS) reported robust Q3 results with revenue growth, improved EBITDA, and positive cash flow, reflecting operational strength and financial stability.
Strategic initiatives like the sale of the rehabilitation business demonstrate a focus on optimizing the portfolio and enhancing shareholder value.
While challenges exist in Q4 growth and business transitions, Bioventus remains well-positioned to leverage opportunities in high-demand medical solutions and international markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2023, and provided its financial guidance for full-year 2024.

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

DURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 12, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

Shares of BVS are up more than 100% over the past year amid an ongoing financial turnaround. The company is benefiting from strong demand for its portfolio of minimally invasive medical treatment including therapeutic injections for osteoarthritis. Shares are attractively priced ahead of the Q4 earnings report where we expect management to deliver positive 2024 guidance.

Bioventus: Bullish On Path To Profitability

DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021, July 11, 2022 and March 31, 2023 (the “Credit Agreement”).

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

DURHAM, N.C., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert (Rob) Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company.

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth

Bioventus Names Robert Claypoole as President and Chief Executive Officer

DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Bioventus Inc. (NASDAQ:BVS ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Tony Bihl - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Lilia-Celine Lozada - JPMorgan Bill Plovanic - Canaccord Operator Thank you for standing by. My name is Dustin, and I will be your conference operator today.

Bioventus Inc. (BVS) Q3 2023 Earnings Call Transcript

DURHAM, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023.

Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

DURHAM, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market opens on Tuesday, November 7, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023

Bioventus Inc. is attempting to move forward from disappointing results in recent years including the failed acquisition of "CartiHeal." The company expects growth to reaccelerate into 2024 as recent pricing pressures stabilize. We expect Bioventus Inc. shares to remain volatile but see an upside as earnings improve going forward.

Bioventus Stock: Improving Outlook Keeps It Interesting

Royal Philips

RadNet

We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.

3 Value Medical Stocks to Buy for Safety Amid Market Volatility

DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET.

Bioventus to Present at the Cantor Global Healthcare Conference

DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET.

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Amarin Corporation Plc

CommScope Hld

1847 Holdings LLC

Gannett Co.

FiscalNote Holdings Inc

Precigen

The RealReal

Rackspace Technology, Inc.

TFF Pharmaceuticals

Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk.

10 Top Penny Stocks To Buy According To Insiders In August

Investing in penny stocks represents an enticing prospect for those seeking to leverage the stock market's potential gains. Characterized by an inherent risk and the promise of significant rewards, these under-$5 shares often become the subjects of speculation.

7 Penny Stocks To Buy According To Insiders In August

Penny stocks provide a captivating opportunity for those aiming to profit in the stock market. The intrinsic risk and potential rewards associated with these stocks often lead to intense speculation and a quest for remarkable profits.

4 Penny Stocks To Buy According To Insiders In August

Bioventus Inc. (NASDAQ:BVS ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Dave Crawford - VP, IR Tony Bihl - CEO Mark Singleton - SVP and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Robbie Marcus - JPMorgan Operator Thank you for standing by, and welcome to Bioventus, Inc. Second Quarter 2023 Earnings Conference Call. I will now turn the call over to your host for today, Mr.

Bioventus Inc. (BVS) Q2 2023 Earnings Call Transcript

DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023.

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

DURHAM, N.C., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will present at the Canaccord Genuity Global Growth Conference on Thursday, August 10, 2023, at 8:00 a.m. ET.

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

DURHAM, N.C., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market opens on Tuesday, August 8, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

Shares of medical device concern Bioventus Inc. have more than tripled off their May 4th intraday low as a decent Q1 2023 report and the return of its ex-CEO have provided confidence. That said, Bioventus stock is still off over 80% from its all-time high after an aggressive acquisition spree put the company in breach of certain covenants in its credit agreement. With one divestment in process, a just-completed restructuring, and continuing headwinds in its hyaluronic acid business, the recent insider buying merited a deeper dive into this busted IPO.

Bioventus: Return Of The King

DURHAM, N.C., May 23, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. The transaction, announced earlier this month, enables Bioventus' improved focus on execution and delivers approximately $30 million of net closing proceeds, which will be used for debt repayment.

Bioventus Completes Divestiture of its Wound Business

Canoo

NovaBay Pharmaceuticals

Understanding the stock market can be a challenging endeavor, yet it offers vast potential for substantial gains, particularly when it comes to penny stocks. Penny stocks, which typically trade below $5 per share, offer an accessible route to market participation, often piquing the interest of investors seeking higher returns with lower capital.

Looking for Undervalued Penny Stocks? Use These Tips

180 Life Sciences 

Take a look at these 3 industries to find penny stocks in.

News for Bioventus Stock (BVS)